Overdose continues to drive mortality among people with opiate use disorders 81 worldwide (1). There are approximately 1.3 million people with opiate use disorder in Europe 82
(2), with Ireland having one of the highest rates of all European countries (3). Irish general 83 practitioners (GPs) play a key role in providing opiate agonist treatment (primarily 84 methadone), and have frequent contact with people who use opiates (4, 5). Ireland 85 experiences a high rate of fatal drug overdose, with many cases involving people who have 86 an opiate use disorder. For instance in 2013, more people died due to opiate overdose than all 87 those who died in road traffic accidents (249 vs 190) (6, 7). Overdose prevention and 88 management have been recognised as key issues for GPs who care for patients with opiate 89 use disorders (8). 90 91 Naloxone is an effective opiate antagonist that can be distributed in the community to 92 treat opiate overdose (9); however, to date, its use in Ireland has largely been limited to 93 doctors, nurses and paramedics. The World Health Organisation recommends that people 94 likely to witness an opiate overdose should have access to naloxone and be instructed in its 95 administration (10). Coordinated take-home naloxone schemes have been available in 96 Scotland and Wales since 2011 (11); however, despite a significant problem with opiate-97 related deaths, Ireland has lagged behind its neighbours on this issue (12). Policy initiatives to 98 allow lay access to naloxone are being developed (13) but the role of general practice in such 99 initiatives has not been established, despite frequent contact with people who use opiates. 100
Previous work by this group has explored the experience and views of trainee GPs, in relation 101 to opiate addiction (14). The perspective of established Irish GPs is also highly relevant, but 102 has not previously been documented. Ultimately this group determine the policies and 103 procedures of their own practices and influence the education and training of future GPs, The 104 purpose of this study is to examine the views and experiences of Irish GPs toward opiate 105 addiction and overdose, to inform policy and practice in this area. 106
METHODS 107
We contacted all GPs (N=714) affiliated with the Department of Academic General 108 Practice, University College Dublin (UCD) by mail in October 2015 and invited them to 109 participate in a paper-based, anonymous postal survey. A reminder letter was sent three 110 weeks after the initial mailing. The cohort of GPs surveyed maintain links with UCD through 111 their roles as undergraduate tutors in general practice, or by involvement in UCD general For the 110 GPs prescribing methadone versus the 331 GPs who do not, methadone 164 prescribers were more likely to work in an urban area (63% vs 30% p<0.001), have patients 165 using illicit opiates (93% vs. 70%, p<0.001) and be willing to take part in a naloxone 166 distribution project (43% vs 28% p<0.01). Regarding whether a GP was in favour of wider 167 naloxone distribution, there was no significant difference between those prescribing and those 168 not prescribing methadone (74% vs 64% p>0.05). Intranasal naloxone was the preferred route 169 for lay delivery of naloxone (mean rank = 1.34), when ranked from first (1) to fourth (4) 170 preference, and a large majority of GPs who responded (81.7% 331/405) reported it as their 171 first preference. This was significantly higher than formulations of naloxone with an 172 injectable single dose (mean = 2.35, p<0.001) or an injectable multi-dose (mean = 3.22, 173 p<0.001), with only 12.8% (47/367) and 3.3% (11/338) respectively of those who replied 174 expressing these as their first preference. 
Strengths and limitations 202
Although this study involved a substantial cross section of Irish general practice, the 203 fact that it involved a targeted sample of GPs affiliated to a major academic centre may limit 204 its representativeness of the wider GP population. The survey instrument used for this study 205 and our earlier study of GP trainees was developed specifically for these purposes and has not 206 been formally assessed in terms of reliability and validity, although it was piloted at one 207 practice site and revised prior to large-scale use. While this study achieved a response rate of 208 63%, it is possible that non-responding GPs may have differed in their experience and 209 attitudes toward opiate addiction and overdose, potentially skewing results. Despite the above 210 limitations, this study is helpful in identifying a sub-population of GPs who provide care to 211 patients with opiate addiction, who see a benefit in wider naloxone distribution and who 212 support distribution initiatives. 213
This study offers an important perspective concerning overdose response and will be 214 helpful in informing future policy initiatives. Despite this observation, the findings must be 215 viewed as representing the clinician's perspective, and one that will need to be balanced with 216 a pragmatic, real-world, community understanding. In reality, when an individual suffers an 217 overdose, it will be the reaction of the surrounding bystanders -whether peers, family 218 members or other individuals -that will be crucial to survival. Research from Ireland has 219 demonstrated high levels of experience of witnessed drug overdose among people with opiate 220 use disorder (22). Previous studies have shown a clear willingness to intervene on the part of 221 those who witness opiate overdose (23, 24). Any planned initiative for GP naloxone 222 provision will need to integrate the clinician's perspective with a pragmatic understanding of 223 the real-world challenge of lay response to witnessed opiate overdose in Ireland. In turn, 224 however, GPs may be well placed to recruit and support family members or friends of drugs 225 users as 'naloxone rescuers', given their local knowledge, continuing relationships with 226 patients and families and potential to identify drug users at higher risk. while some GPs perceived community naloxone provision to be more appropriate for 239 specialist drug services, GPs did express tentative willingness to be involved (27). However, 240 this important study did highlight concerns expressed among GPs regarding training, 241 knowledge and the level of experience necessary to enable participation. The issue of 242 medico-legal uncertainty regarding innovative schemes has also been raised as a further 243 barrier to community naloxone provision (28, 29). These issues, among others were not 244 addressed in our study and will need to be explored further elsewhere. 245
Our research finding that only a minority of general practices and an even smaller 246 percentage of GP training practices provide the opiate agonist treatment methadone, 247 compares poorly with data from other countries. In Scotland, 44% of GPs were providing 248 methadone in 2008 (30), while in some regions of Switzerland, GPs are known to provide the 249 majority of opiate agonist treatment (31). Research from England and Wales suggested that 250 over time an increasing number of GPs have become involved in opiate agonist provision. 251
However, in keeping with the findings from our study, more patients with opiate use disorder 252 were seen for general medical care than were prescribed methadone by their GP (32). This Three important conclusions can be drawn from the findings of our study. Firstly, significant 280 differences emerge between the quarter of GPs whose practices prescribe opiate agonist 281 treatment and the three quarters who do not. GPs who prescribed methadone appear to be 282 more willing to participate in an initiative to increase access to naloxone in the community, 283 and as such would be a logical cohort to pilot a take-home naloxone programme in primary 284 care. Previous research in Ireland has identified the high-risk geographical locations where 285 overdose occurs most frequently (17). GPs who are working in these areas and are already 286 prescribing methadone could be targeted in the first instance. The relatively low level of 287 involvement of GPs in opiate agonist treatment and their concentration in urban areas in the 288 east of the country, contrasts sharply with the well-reported increase in opiate dependence in 289 all areas of the country (40). Efforts to engage larger numbers of GPs in poorly served parts 290 of the country, are also essential. 291
Secondly, the observation that a majority of training practices do not provide 292 exposure to opiate agonist treatment is likely to be a major limiting factor in the future 293 development of competency in this area. Currently, GP trainees are unlikely to have acquired 294 the necessary training and experience to enable participation in either opiate agonist treatment 295 or overdose prevention in general practice. This issue should be addressed as a matter of 296 urgency. 297
Finally, GPs express a clear preference for intranasal naloxone. To date, there is no 298 licenced preparation of intranasal naloxone available in Ireland, however as previously 299 mentioned the US FDA has recently approved a bespoke intranasal product (39). Given the 300 wide prevalence of problem opiate use and lethal potential for overdose, an appropriate take-301 home intranasal product and primary-care training package should be developed as a matter 302 of urgency. 303 304 
